Today, we present Helix AI, a novel AI-powered discovery engine that integrates generative chemistry, multi-omics insights, and predictive analytics into one unified platform.Acting as an agentic experiment designer, Helix AI combines hundreds of tools and datasets, rapidly generating, prioritizing, and optimizing workflows from target ID to IND. With adaptive learning and scientist-in-the-loop control, it helps R&D organizations accelerating discovery timelines from years to weeks while facilitating the discovery of novel therapeutic candidates across modalities. Helix AI represents an inflection point in how AI can drive value in R&D programs.Join us to learn more about how it is changing drug discovery research for the better.
Marcos Camara Donoso
Steve Gately
Steve leads NVIDIA’s engagement with strategic ISV platform partners in the healthcare sector, helping them accelerate their go-to-market initiatives. By integrating partners’ specialized tools and data with NVIDIA’s advanced training and inference technologies, Steve and his team develop cohesive strategies that drive success across key AI-powered healthcare use cases.
Helix AI
Website: https://helixai.com/
HelixAI is a specialist scientific technology company focused on accelerating research and development for biopharmaceutical organizations. Its platform, JarvisAI, enables scientific teams to design and execute in silico R&D workflows that support a wide range of operations from early-stage drug discovery to scale-up and bioproduction. By integrating scientific data from public, private and client domains along with computational models and AI-driven orchestration, JarvisAI helps researchers explore hypotheses more efficiently and prioritize the most promising drug candidates for further development. This approach supports better, faster decision-making combined with optimization of scientific and wet-lab resources.
